Journals / Haydarpaşa Numune Medical Journal / 2021 / Cilt: 61 - Sayı: 3

Effective Risk Factors in the Development of Retinopathy of Prematurity, Screening Results and Intravitreal Ranibizumab Treatment

Pages
264–271
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Week of birth and low birth weight (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The aim is to evaluate the incidence of retinopathy of prematurity within three years in premature babies fol- lowed up in our clinic, to determine the risk factors that play a role in the development of retinopathy, to evaluate intravitreal ranibizumab treatment and its results.
📊
Key Findings & Data:Methods: Babies with a birth weight of ≤32 weeks and/or a birth weight of ≤1500 grams and babies determined to be at risk by the clinician were examined for the development of retinopathy.
💡
Conclusion & Impact:Week of birth and low birth weight (p
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: The aim is to evaluate the incidence of retinopathy of prematurity within three years in premature babies fol- lowed up in our clinic, to determine the risk factors that play a role in the development of retinopathy, to evaluate intravitreal ranibizumab treatment and its results. Methods: Babies with a birth weight of ≤32 weeks and/or a birth weight of ≤1500 grams and babies determined to be at risk by the clinician were examined for the development of retinopathy. Risk factors including week of birth, birth weight, mode of delivery, gender, APGAR scores, need for mechanical ventilation, ≥40% oxygen therapy, duration of oxygen therapy, surfactant therapy, acidosis, hypoxia, sepsis, erythrocyte transfusion, intraventricular hemorrhage, apnea and anemia were compared between cases who developed or did not develop retinopathy of prematurity. Results: The mean birth week of the babies was 30.1±0.24 weeks (23-36 weeks), and the mean birth weight was 1362.3±378.6 grams (450-2020 grams). Retinopathy of prematurity at different stages was detected in 21 (16.2%) of 130 patients. Eight (6.1%) of all patients screened for retinopathy of prematurity required treatment. Intravitreal ranibizumab was administered to seven patients (5.3%) with Stage III retinopathy, and both ranibizumab and laser therapy were applied to one patient with Stage IV retinopathy. Week of birth and low birth weight (p

🔖

Cite This Article

ÖZKAN, B., ARCAGÖK, B. C. (2022). Effective Risk Factors in the Development of Retinopathy of Prematurity, Screening Results and Intravitreal Ranibizumab Treatment. Haydarpaşa Numune Medical Journal, Cilt: 61 - Sayı: 3, 264–271. https://ajindex.com/articles/651398

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Fierson WM, American Academy of Pediatrics Section on Oph- thalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening ex- amination of premature infants for retinopathy of prematu- rity. Pediatrics 2013;131:189–95
  2. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77–82
  3. Fleck BW. Management of retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98:454–6
  4. Ye Sun, Hellström A, Smith LEH. Retinopathy of prematurity. In: Martin RJ, Fanaroff AA, Walsh MC (editors). Fanaroff and Martin’s neonatal perinatal medicine: diseases of the fetus and infant. Missouri: Mosby Elsevier, 2020:1970–8
  5. Quinn GE, Ying G, Bell EF, Donohue PK, Morrison D, Tomlinson LA, et al. Incidence and early course of retinopathy of prema- turity. JAMA Ophthalmol 2018;136:1383–9
  6. McCauley K, Chundu A, Song H, High R, Suh D. Implemen- tation of a Clinical Prediction Model Using Daily Postnatal Weight Gain, Birth Weight, and Gestational Age to Risk Stratify ROP. J Pediatr Ophthalmol Strabismus 2018;55:326–34
  7. Fortes Filho JB, Eckert GU, Valiatti FB, Dos Santos PG, da Costa MC, Procianoy RS. The influence of gestational age on the dy- namic behavior of other risk factors associated with retinopa- thy of prematurity (ROP). Graefes Arch Clin Exp Ophthalmol 2010;248:893–900
  8. Early Treatment For Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopa- thy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–94
  9. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991–9
  10. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and Early Course of Retinopathy of Prema- turity. Ophthalmology 2020;127:S84–96
  11. Chow PPC, Yip WWK, Ho M, Lok JYC, Lau HHW, Young AL. Trends in the incidence of retinopathy of prematurity over a 10.year period. Int Ophthalmol 2019;39:903–9
  12. Luk AS, Yip WW, Lok JY, Lau HH, Young AL. Retinopathy of pre- maturity: applicability and compliance of guidelines in Hong Kong. Br J Ophthalmol 2017;101:453–6
  13. Schaffer DB, Palmer EA, Plotsky DF, Metz HS, Fl